NewAmsterdam Pharma (NASDAQ:NAMSW) Stock Price Down 19.2% – What’s Next?

NewAmsterdam Pharma (NASDAQ:NAMSW) fell 19.2% on Tuesday . The stock traded as low as $20.05 and last traded at $20.9810. 341 shares were traded during trading, a decline of 62% from the average session volume of 891 shares. The stock had previously closed at $25.97.

NewAmsterdam Pharma Stock Down 22.8%

The company has a fifty day moving average of $22.95 and a 200 day moving average of $22.17.

Hedge Funds Weigh In On NewAmsterdam Pharma

An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC grew its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) by 1.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 245,000 shares of the company’s stock after buying an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon?like peptide?1 (GLP-1) receptor agonist currently in early clinical trials.